Prothena Plc (NASDAQ: PRTA)
Prothena Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Prothena Plc Company Info
Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
News & Analysis
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
Promising drug candidates could lead to a best-in-class Alzheimer's treatment.
Lessons to Learn From April's Biotech Blowups
Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.
Why Prothena Corporation plc Is Imploding Today
Shares plunge after the company announces that it is halting development of its lead pipeline candidate. Here's what investors need to know.
Why Prothena Corp plc Shot 14.4% Higher Today
The company's landed a new collaboration partner and a new investor.
The Reason Behind Prothena Corporation PLC's Plunge of as Much as 25%
A sudden executive departure leaves Prothena's shareholders worried.
Why Prothena Corp plc Skyrocketed 43% in July
An advancing pipeline of drugs targeting important diseases could provide market-moving news over the coming year.
3 Best Stocks for Risk-Tolerant Investors
Our Motley Fool contributors like these high-risk stocks for the long term, and perhaps you should, too.
Forget Gilead Sciences: These Stocks Doubled Last Year
Interested in stocks with huge growth potential? These three stock at least doubled last year hold promise for big gains in the years ahead.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.